Ido Wolf

Summary

Affiliation: Rabin Medical Center
Country: Israel

Publications

  1. ncbi request reprint The mitogen-activated protein kinase signaling cascade: from bench to bedside
    Ido Wolf
    Department of Internal Medicine E, Sheba Medical Center, Tel Hashomer, Israel
    Isr Med Assoc J 4:641-7. 2002
  2. doi request reprint Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer
    I Wolf
    Institute of Oncology Chaim Sheba Medical Center, Ramat Gan, Israel
    Oncogene 27:7094-105. 2008
  3. ncbi request reprint Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study
    Ido Wolf
    The Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel
    Cancer 112:731-6. 2008
  4. ncbi request reprint Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest
    Ido Wolf
    Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, CA, USA
    Int J Oncol 30:1529-37. 2007
  5. ncbi request reprint Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer
    Ido Wolf
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA
    Breast Cancer Res Treat 105:139-55. 2007
  6. doi request reprint Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin
    I Wolf
    The Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel
    Oncogene 29:26-33. 2010
  7. ncbi request reprint 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer
    Ido Wolf
    Division of Hematology Oncology, Cedars Sinai Medical Center, University of California at Los Angeles School of Medicine, Los Angeles, CA 90048, USA
    Cancer Res 66:7818-23. 2006
  8. ncbi request reprint Association between diabetes mellitus and adverse characteristics of breast cancer at presentation
    Ido Wolf
    The Institute of Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel
    Eur J Cancer 42:1077-82. 2006
  9. ncbi request reprint Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients
    Ido Wolf
    The Institute of Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Cancer 106:966-73. 2006
  10. doi request reprint Epigenetic silencing of the tumor suppressor klotho in human breast cancer
    Tami Rubinek
    The Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel
    Breast Cancer Res Treat 133:649-57. 2012

Collaborators

Detail Information

Publications21

  1. ncbi request reprint The mitogen-activated protein kinase signaling cascade: from bench to bedside
    Ido Wolf
    Department of Internal Medicine E, Sheba Medical Center, Tel Hashomer, Israel
    Isr Med Assoc J 4:641-7. 2002
  2. doi request reprint Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer
    I Wolf
    Institute of Oncology Chaim Sheba Medical Center, Ramat Gan, Israel
    Oncogene 27:7094-105. 2008
    ..These data suggest klotho as a potential tumor suppressor and identify it as an inhibitor of the IGF-1 pathway and activator of the FGF pathway in human breast cancer...
  3. ncbi request reprint Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study
    Ido Wolf
    The Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel
    Cancer 112:731-6. 2008
    ..To the authors' knowledge, the association between the RS and clinicopathologic characteristics has been studied in randomized and case-control trials, but not in the general population...
  4. ncbi request reprint Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest
    Ido Wolf
    Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, CA, USA
    Int J Oncol 30:1529-37. 2007
    ..Our data suggest that HNK is a systemically available, non-toxic inhibitor of breast cancer growth and should be examined for clinical applications...
  5. ncbi request reprint Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer
    Ido Wolf
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA
    Breast Cancer Res Treat 105:139-55. 2007
    ..Thus, unmasking of epigenetic silencing in breast cancer enabled us to discover a large number of candidate tumor suppressor genes. Further analysis suggested a role of one of these genes, PTCH, in breast cancer tumorigenesis...
  6. doi request reprint Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin
    I Wolf
    The Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel
    Oncogene 29:26-33. 2010
    ..These data suggest KL-VS as a breast and ovarian cancer risk modifier among BRCA1 mutation carriers. If validated in additional cohorts, the presence of KL-VS may serve as a predictor of cancer risk among BRCA1 mutation carriers...
  7. ncbi request reprint 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer
    Ido Wolf
    Division of Hematology Oncology, Cedars Sinai Medical Center, University of California at Los Angeles School of Medicine, Los Angeles, CA 90048, USA
    Cancer Res 66:7818-23. 2006
    ..Our results indicate for the first time that 15-PGDH may be a novel tumor suppressor gene in breast cancer, and suggest that this enzyme can modulate the ER pathway...
  8. ncbi request reprint Association between diabetes mellitus and adverse characteristics of breast cancer at presentation
    Ido Wolf
    The Institute of Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel
    Eur J Cancer 42:1077-82. 2006
    ..Moreover, after adjustment for BMI, breast cancer among diabetic patients was more often hormone receptor negative. Our results show that diabetes mellitus is associated with negative prognostic factors at breast cancer presentation...
  9. ncbi request reprint Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients
    Ido Wolf
    The Institute of Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Cancer 106:966-73. 2006
    ..Cancer cachexia is a complex metabolic state, characterized by loss of muscle mass and adipose tissue together with anorexia. The authors hypothesized that responses of these hormones may be attenuated in cancer cachexia...
  10. doi request reprint Epigenetic silencing of the tumor suppressor klotho in human breast cancer
    Tami Rubinek
    The Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel
    Breast Cancer Res Treat 133:649-57. 2012
    ..Klotho expression and methylation may, therefore, serve as early markers for breast tumorigenesis...
  11. doi request reprint Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase
    Naoki Wakimoto
    Division of Hematology Oncology, Cedars Sinai Medical Center University of California at Los Angeles School of Medicine, USA
    Cancer Res 68:6978-86. 2008
    ..Our studies provide evidence that the up-regulation of 15-PGDH induced by NSAIDs has the potential to inhibit growth of GBM, in part, by up-regulation of p21 possibly independent from COX-2 enzymatic function...
  12. doi request reprint Hormone receptor expression is associated with a unique pattern of metastatic spread and increased survival among HER2-overexpressing breast cancer patients
    Shani Paluch-Shimon
    Institute of Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Am J Clin Oncol 32:504-8. 2009
    ....
  13. ncbi request reprint FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer
    Ido Wolf
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA
    Int J Cancer 120:1013-22. 2007
    ..Yet, FOXA1 expression was noted in a subset of the ER-negative tumors. Taken together, our findings suggest a growth inhibitory role for FOXA1, and identify it as a novel, potential prognostic factor in breast cancer...
  14. doi request reprint Association between very young age and adverse characteristics of breast cancer at presentation amongst Israeli women
    Shani Paluch-Shimon
    The Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel
    Am J Clin Oncol 34:219-22. 2011
    ..Studies have suggested an association between breast cancer at a young age, poorer outcome, and adverse clinical and pathologic characteristics. It is unclear whether age is an independent prognostic factor...
  15. pmc The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers
    Yael Laitman
    The Susanne Levy Gertner Oncogenetics Unit 1, The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel
    Breast Cancer Res Treat 132:1119-26. 2012
    ..The risk did not change when carriers of the 6174delT mutation were excluded. There was a lack of association of the KL-VS Klotho variant with either breast or ovarian cancer risk in BRCA1 and BRCA2 mutation carriers...
  16. doi request reprint KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF-I signaling in pancreatic cancer
    Lilach Abramovitz
    Institute of Oncology, The Chaim Sheba Medical Center, Ramat Gan, Tel Aviv, Israel
    Clin Cancer Res 17:4254-66. 2011
    ..Klotho is expressed in the normal pancreas and both the IGF-I and FGF pathways are involved in pancreatic cancer development. We, therefore, undertook to study the expression and activity of klotho in pancreatic cancer...
  17. doi request reprint The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells
    Hagai Ligumsky
    Institute of Oncology, Chaim Sheba Medical Center, 52621 Ramat Gan, Israel
    Breast Cancer Res Treat 132:449-61. 2012
    ..Reduced GLP-1 levels may, therefore, serve as a novel link between obesity, diabetes mellitus, and breast cancer...
  18. ncbi request reprint Diabetes mellitus and breast cancer
    Ido Wolf
    Institute of Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Lancet Oncol 6:103-11. 2005
    ..Moreover, diabetes and its complications can adversely affect cancer therapy and the use of screening, which will thus affect the outcome of patients with breast cancer...
  19. doi request reprint High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer
    Shani Paluch-Shimon
    The Institute of Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Acta Oncol 47:1564-9. 2008
    ....
  20. doi request reprint Cyclophosphamide triggers follicle activation and "burnout"; AS101 prevents follicle loss and preserves fertility
    Lital Kalich-Philosoph
    Fertility Preservation Research Laboratory, IVF Unit, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel
    Sci Transl Med 5:185ra62. 2013
    ..By preventing this activation, AS101 shows potential as an ovarian-protective agent, which may be able to preserve fertility in female cancer patients...
  21. doi request reprint Different patterns of human serum procollagen C-proteinase enhancer1 (PCPE1)
    Shlomit Mesilaty-Gross
    Metabolic Enzymatic Laboratory, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Clin Chim Acta 403:76-80. 2009
    ..Thus, in this study we sought to determine if serum PCPE1 (sPCPE1), a regulator of collagen formation, can be used as a diagnostic marker of collagen metabolism/remodeling...